葛兰素史克(GSK.US)2019年业绩预期同比持平，股价上涨或因疫苗业务强劲

智通财经网2020-02-04

葛兰素史克(GSK.US)将于1月5日美股盘前发布2019年四季度财报，市场普遍预计Q4每股收益69美分，Zacks预计70美分。公司预计全年每股收益将与上年同期持平，去年同期的每股收益是1.474英镑，归母净利润36.23亿英镑，营收308.21亿英镑。葛兰素史克公司四季度股价上涨14.46%。三季度业绩回顾公司第三季度实现收入45亿英镑，同比增长3%。销售额主要来自疫苗，第三季度增长15%至...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

壹陆常虹
2020-02-09
壹陆常虹
和辉瑞合并后就没啥进度！和英国脱欧一样漫长！

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2008828421?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/e559c5a8390713a5a8d4b07a2667368d","is_english":false,"pubTime":"2020-02-04 15:16","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2008828421","market":"us","top_or_hot":-1,"title":"葛兰素史克(GSK.US)2019年业绩预期同比持平，股价上涨或因疫苗业务强劲","media":"智通财经网","content":"<div>\n<p>葛兰素史克(GSK.US)将于1月5日美股盘前发布2019年四季度财报，市场普遍预计Q4每股收益69美分，Zacks预计70美分。公司预计全年每股收益将与上年同期持平，去年同期的每股收益是1.474英镑，归母净利润36.23亿英镑，营收308.21亿英镑。葛兰素史克公司四季度股价上涨14.46%。三季度业绩回顾公司第三季度实现收入45亿英镑，同比增长3%。销售额主要来自疫苗，第三季度增长15%至...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2020-02-04/doc-iimxyqvz0216314.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>葛兰素史克(GSK.US)2019年业绩预期同比持平，股价上涨或因疫苗业务强劲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n葛兰素史克(GSK.US)2019年业绩预期同比持平，股价上涨或因疫苗业务强劲\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-02-04 15:16 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2020-02-04/doc-iimxyqvz0216314.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>葛兰素史克(GSK.US)将于1月5日美股盘前发布2019年四季度财报，市场普遍预计Q4每股收益69美分，Zacks预计70美分。公司预计全年每股收益将与上年同期持平，去年同期的每股收益是1.474英镑，归母净利润36.23亿英镑，营收308.21亿英镑。葛兰素史克公司四季度股价上涨14.46%。三季度业绩回顾公司第三季度实现收入45亿英镑，同比增长3%。销售额主要来自疫苗，第三季度增长15%至...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2020-02-04/doc-iimxyqvz0216314.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2020-02-04/doc-iimxyqvz0216314.shtml","article_id":"2008828421","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/e559c5a8390713a5a8d4b07a2667368d"],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2020-02-04/doc-iimxyqvz0216314.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2008828421","pubTimestamp":1580800560,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"葛兰素史克(GSK.US)将于1月5日美股盘前发布2019年四季度财报，市场普遍预计Q4每股收益69美分，Zacks预计70美分。公司预计全年每股收益将与上年同期持平，去年同期的每股收益是1.474英","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"GSK":"葛兰素史克","GSK.UK":"葛兰素史克"},"translate_title":"GlaxoSmithKline (GSK.US) 2019 Performance Expected to Be Flat Year-on-Year, Stock Price Rising or Due to Strong Vaccine Business","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":0.6,"GSK.UK":0.6},"content_text":"葛兰素史克(GSK.US)将于1月5日美股盘前发布2019年四季度财报，市场普遍预计Q4每股收益69美分，Zacks预计70美分。公司预计全年每股收益将与上年同期持平，去年同期的每股收益是1.474英镑，归母净利润36.23亿英镑，营收308.21亿英镑。葛兰素史克公司四季度股价上涨14.46%。三季度业绩回顾公司第三季度实现收入45亿英镑，同比增长3%。销售额主要来自疫苗，第三季度增长15%至23亿英镑，其消费者保健部门也报告了强劲的业绩增长，同期收入增长3%至25亿英镑。股票评级Zacks给予评级“持有”在过去四个季度中，该公司的收益平均每季度都超过预期17.23%影响业绩的因素考虑到对带状疱疹疫苗、带状疱疹疫苗和呼吸道药物的强劲需求，葛兰素史克的制药业务可能受到了推动。然而，艾滋病毒领域日益激烈的竞争，尤其是针对三种药物治疗方案的竞争，可能会影响销售。在对Trelegy Ellipta和Nucala的强劲需求的支撑下，呼吸类产品的销售增长趋势可能会在第四季度继续下去。Nucala在9月份将6岁及以上患有严重嗜酸性哮喘的儿童纳入标签范围，这可能推动了该药在本季度的销售。然而，面临竞争和定价压力的呼吸系统药如Advair和Relvar/Breo Ellipta可能会对葛兰素史克即将公布的这个季度的销售产生不利影响。葛兰素史克Benlysta第三季度的销售增长达到创纪录水平。在第四季度，该药物的标签扩大到包括五岁以上的欧洲患有狼疮的儿童，这可能促进了该季度的销售。此外，从诺华制药收购的脑膜炎疫苗Bexsero的销量在前三个季度出现了增长。这种趋势很可能在第四季度继续下去。然而，Menveo的销量在前一季度略有下降。对这些疫苗的需求每个季节都有波动，因此销售可能会有所不同。今年8月，葛兰素史克与辉瑞制药成立了一家合资企业，以打造全球最大的消费者医疗保健业务。葛兰素史克持有合资公司68%的控股权，辉瑞持有32%。其中口腔保健产品可能推动了销售额的增长。葛兰素史克将利用其已建立的大流行性流感疫苗佐剂平台技术，加强对该病毒的有效疫苗的开发。在一些疫苗中添加佐剂以增强免疫应答，从而产生比单独使用疫苗更强、更持久的抗感染免疫。佐剂的使用在流感大流行情况下是至关重要的，因为它可以减少每剂疫苗所需的抗原量，从而使更多的人可以生产和获得更多的疫苗剂量。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":914877827,"gmtCreate":1581253616469,"gmtModify":1704343708934,"author":{"id":"3536293366247859","authorId":"3536293366247859","name":"壹陆常虹","avatar":"https://static.tigerbbs.com/10da102863779b713126d1c918640ded","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3536293366247859","authorIdStr":"3536293366247859"},"htmlText":"和辉瑞合并后就没啥进度！和英国脱欧一样漫长！","listText":"和辉瑞合并后就没啥进度！和英国脱欧一样漫长！","text":"和辉瑞合并后就没啥进度！和英国脱欧一样漫长！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/914877827","repostId":2008828421,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2008828421"}